Michael Cecchini, MD
Associate Professor of Medicine (Medical Oncology)Cards
Additional Titles
Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers
Medical Oncology Section Lead for National Accreditation Program for Rectal Cancer, Internal Medicine
Co-Director, GI Clinical Research Team
Phase 1 Investigator, Yale Cancer Center
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers
Medical Oncology Section Lead for National Accreditation Program for Rectal Cancer, Internal Medicine
Co-Director, GI Clinical Research Team
Phase 1 Investigator, Yale Cancer Center
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers
Medical Oncology Section Lead for National Accreditation Program for Rectal Cancer, Internal Medicine
Co-Director, GI Clinical Research Team
Phase 1 Investigator, Yale Cancer Center
Contact Info
About
Titles
Associate Professor of Medicine (Medical Oncology)
Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers; Medical Oncology Section Lead for National Accreditation Program for Rectal Cancer, Internal Medicine; Co-Director, GI Clinical Research Team; Phase 1 Investigator, Yale Cancer Center
Appointments
Medical Oncology and Hematology
Associate Professor on TermPrimary
Other Departments & Organizations
- Center for Gastrointestinal Cancers
- Developmental Therapeutics
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Internal Medicine
- Janeway Society
- Medical Oncology & Hematology
- Medical Oncology and Hematology
- Oligometastatic Cancer Program
- Subset Medical Oncology Faculty
- Yale Cancer Center
- Yale Medicine
Education & Training
- Hematology / Oncology Fellow
- Yale New Haven Hospital (2018)
- Internal Medicine Resident
- Yale New Haven Hospital (2015)
- MD
- Albert Einstein College of Medicine (2012)
- BS
- University of California, Santa Cruz, Cell, Molecular, and Developmental Biology (2008)
Research
Overview
Medical Research Interests
ORCID
0000-0003-3504-0128
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Jill Lacy, MD
Jeremy Kortmansky, MD
Kimberly L. Johung, MD, PhD
Patricia LoRusso, DO
Joanna Gibson, MD, PhD
Wei Wei, PhD
DNA Repair
Immunotherapy
Publications
2025
Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies
Janjigian Y, Cecchini M, Shitara K, Enzinger P, Wainberg Z, Chau I, Satoh T, Lee J, Nebozhyn M, Loboda A, Kobie J, Vajdi A, Shih C, Cristescu R, Cao Z. Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies. JCO Precision Oncology 2025, 9: e2400456. PMID: 40117530, PMCID: PMC11949223, DOI: 10.1200/po-24-00456.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsTumor mutational burdenHomologous recombination deficiencyMicrosatellite instability-highGenomic characteristicsChromosomal instabilityKEYNOTE-062Late-stage GCKEYNOTE-059KEYNOTE-061Molecular subtypesAsian originWhole-exome sequencingGastric cancerSubtype prevalenceEpstein-Barr virus-positiveHomologous recombination deficiency scoresPretreatment tumor samplesWES dataGene expression signaturesCancer Genome AtlasMicrosatellite instability-high subtypeRNA sequencingGenomic landscapeEarly-stage GCGenomic alterations47P Final analysis of the randomized phase II cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer and potential serum biomarkers
Schickler M, Mercade T, Cecchini M, Garcia-Carbonero R, Golan T, Perets R, Borazanci E, Trujillo M, Ponz M, Al-Hallak M, Pant S, Boni V, Saavedra O, De Miguel M, Leal A, Martin A, Nadal T, David H, Reuveni H. 47P Final analysis of the randomized phase II cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer and potential serum biomarkers. ESMO Open 2025, 10: 104206. DOI: 10.1016/j.esmoop.2025.104206.Peer-Reviewed Original ResearchOlaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Cecchini M, Pilat M, Uboha N, Azad N, Cho M, Davis E, Ahnert J, Tinoco G, Shapiro G, Khagi S, Powers B, Spencer K, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Narayan A, Vu D, Patel A, Niger M, Doroshow D, Durecki D, Boerner S, Bindra R, Ivy P, Shyr D, Shyr Y, LoRusso P. Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer 2025, 131: e35755. PMID: 39917990, DOI: 10.1002/cncr.35755.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsProgression-free survivalHomologous recombination deficiencyClinical benefitNational Cancer InstituteIDH inhibitorsMedian progression-free survivalAccumulation of 2-hydroxyglutaratePhase 2 clinical trialIsocitrate dehydrogenase inhibitorsMedian overall survivalSingle-agent activityNovel combination therapiesEnhance patient selectionSubgroup of patientsOverall survivalOpen-labelCombination therapyIDH mutationsPatient selectionRecombination deficiencySolid tumorsTumor progressionClinical trialsOlaparibCholangiocarcinoma
2024
Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms
Uhlig J, Nie J, Gibson J, Cecchini M, Stein S, Lacy J, Kunz P, Kim H. Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms. Scientific Reports 2024, 14: 30536. PMID: 39690170, PMCID: PMC11652651, DOI: 10.1038/s41598-024-81518-4.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsGEP-NEN patientsGastroenteropancreatic neuroendocrine neoplasmsOverall survivalGEP-NENsTreatment patternsSystemic therapyNeuroendocrine neoplasmsAssociated with improved survivalLow-grade diseaseNational Cancer DatabaseLonger overall survivalSite-specific incidenceDisease specific factorsG3 NENSurgical resectionCancer DatabaseImproved survivalLow-stageCox regressionImprove outcomesPatientsIncidence increasesInternational guidelinesInvestigate incidenceSurvivalMolecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations
Yasin F, Sokol E, Vasan N, Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Zhang J, Ross J, Cecchini M. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. The Oncologist 2024, 29: 1059-1067. PMID: 39401325, PMCID: PMC11630746, DOI: 10.1093/oncolo/oyae259.Peer-Reviewed Original ResearchConceptsAdvanced colorectal cancerPIK3CA mutationsColorectal cancerPI3K inhibitionPI3K inhibitorsBurden of colorectal cancerActivating mutationsResponse to PI3K inhibitionSensitive to PI3K inhibition.Foundation Medicine databaseMetastatic colorectal cancerClinically relevant mutationsMicrosatellite instability-highPI3K signalingTumor DNAPIK3CA variantsClinical carePIK3CA oncogeneClinical variablesE545KGenomic profilingPIK3CAE542KMedicine DatabasePatientsDeep-Transfer-Learning–Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Cancer
Kim S, Kim S, Kim E, Cecchini M, Park M, Choi J, Kim S, Hwang H, Kang C, Choi H, Shin S, Kang J, Lee C. Deep-Transfer-Learning–Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Cancer. JCO Clinical Cancer Informatics 2024, 8: e2400021. PMID: 39151114, DOI: 10.1200/cci.24.00021.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsArea under the receiver operating characteristic curveSurvival of patientsCT reportsPancreatic cancerNatural language processingC-indexPredicting survivalOverall survival of patientsTertiary hospitalPredicting 1-year survivalPredicting survival of patientsImproved C-indexSurvival informationPancreatic cancer survivalReceiver operating characteristic curveInternal test data setNLP modelsComputed tomography reportsLanguage processingKorean tertiary hospitalOverall survivalConsecutive patientsActual survivalConcordance indexPatientsPerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchConceptsProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOXAssociation of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma
Botta G, Abdelrahim M, Drengler R, Aushev V, Esmail A, Laliotis G, Brewer C, George G, Abbate S, Chandana S, Tejani M, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi P, Kasi A, Dayyani F, Hanna D, Sharma S, Malhotra M, Aleshin A, Liu M, Jurdi A. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. The Oncologist 2024, 29: 859-869. PMID: 39022993, PMCID: PMC11449101, DOI: 10.1093/oncolo/oyae155.Peer-Reviewed Original ResearchConceptsMolecular residual diseasePancreatic ductal adenocarcinomaPatient survival outcomesCtDNA detectionSurvival outcomesStage I–III pancreatic ductal adenocarcinomaAssociated with shorter DFSMedian follow-up timeFollow-up timeCtDNA levelsResidual diseaseShorter DFSPrognostic factorsPancreatic adenocarcinomaAssociated with patient survival outcomesDuctal adenocarcinomaRetrospective analysisDiagnosed patientsMultivariate analysisSurveillance periodPatientsPlasma samplesTumor informationWhole exomeSurveillance windowProofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer
Cecchini M, Sundar R. Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer. Annals Of Oncology 2024, 35: 582-584. PMID: 38910015, DOI: 10.1016/j.annonc.2024.04.006.Commentaries, Editorials and LettersInterim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.
Macarulla T, Cecchini M, Garcia-Carbonero R, Golan T, Perets R, Borazanci E, Pedregal M, Ponz-Sarvise M, Al Hallak M, Pant S, Boni V, Saavedra O, de Miguel M, Leal A, Muñoz Martín A, Sauri T, Schickler M. Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer. Journal Of Clinical Oncology 2024, 42: lba4143-lba4143. DOI: 10.1200/jco.2024.42.17_suppl.lba4143.Peer-Reviewed Original ResearchConceptsDisease control rateProgression free survivalPancreatic ductal adenocarcinomaCarcinoembryonic antigen cell adhesion molecule 1Nal-IRIGemcitabine/nab-paclitaxelOverall survivalData cut-off dateRandomized phase 2 studyMedian follow-up timeCut-off dateAdequate organ functionAdvanced/metastatic pancreatic cancerPhase 2 studyLog-rank testFollow-up timeCell adhesion molecule 1Adhesion molecule 1Liposomal irinotecanFree survivalLine therapyOpen-labelSystemic therapyPFS-HRPrimary endpoint
Clinical Trials
Current Trials
Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
HIC ID2000033374RoleSub InvestigatorPrimary Completion Date07/31/2025Recruiting ParticipantsColon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
HIC ID2000032928RoleSub InvestigatorPrimary Completion Date03/10/2029Recruiting ParticipantsA Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
HIC ID2000032119RoleSub InvestigatorPrimary Completion Date03/17/2026Recruiting ParticipantsOpen Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors
HIC ID2000032542RoleSub InvestigatorPrimary Completion Date01/01/2026Recruiting ParticipantsA Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
HIC ID2000032188RoleSub InvestigatorPrimary Completion Date10/31/2026Recruiting Participants
Academic Achievements & Community Involvement
activity Clinical Cancer Research, and Journal of Immunotherapy of Cancer
Journal ServiceReviewerDetails2018 - Presentactivity Journal of Immunotherapy of Cancer
Journal ServiceReviewerDetails2018 - Presentactivity Medical Oncology Fellowship Selection Committee
CommitteesMemberDetails2017 - Presentactivity Intern and Resident Selection Committee, Internal Medicine, Yale New Haven Hospital
CommitteesMemberDetails2016 - Presentactivity Yale Cancer Answers
Public ServicePresenter/SpeakerDetails2021 - Present
Clinical Care
Overview
Michael Cecchini, MD, is a medical oncologist who specializes in gastrointestinal cancers, including (but not limited to) colorectal, bile duct, pancreas, esophageal, and stomach cancers. He often cares for patients with advanced gastrointestinal cancers and is an investigator in multiple research trials to help them get treatments that are not always available elsewhere.
“Taking care of patients and spending the time to get to know them is the best part of my job,” Dr. Cecchini says. It helps to draw upon the diverse expertise of colleagues at Smilow and those in non-cancer specialties, he adds. “At Yale we have an excellent multidisciplinary team that will work hard to treat your cancer, manage your symptoms, and deliver the care you deserve as a patient.”
Dr. Cecchini was inspired to become a cancer specialist partly because he wanted to have opportunities to perform research to improve options for his patients. “Few specialties are so integrated with close patient relationships and translational research that can dramatically improve the lives of our patients and minimize side effects,” he says. His translational research includes clinical and lab projects to study DNA damage and the immune response, primarily for colorectal cancer. He is the recipient of a Young Investigator Award from the Conquer Cancer Foundation for research focused on metastatic gastric cancer and 2020 Scholar on the Yale Cancer Center K12 Calabresi Immuno-Oncology Training Program.
Clinical Specialties
Fact Sheets
Gastrointestinal Cancers
Learn More on Yale MedicineColorectal Cancer
Learn More on Yale MedicineSmall Intestine Adenocarcinoma
Learn More on Yale MedicineAnal Cancer
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
News
- April 07, 2025
YCC Publications 2025
- April 02, 2025
Yale Cancer Center Annual Awards
- March 28, 2025
Center for GI Cancers CME Webinar Series: Colorectal Cancer
- March 21, 2025Source: WTNH News 8 (with Dr. Michael Cecchini)
Colorectal Cancer Awareness Month: Exercise can reduce rates and help survivors live longer
Get In Touch
Contacts
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.